ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Cardiac Rhythmology
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1600238
This article is part of the Research TopicAtrial Fibrillation (AF) in Heart Failure with Preserved Ejection Fraction (HFpEF)View all 6 articles
Long-term outcome of catheter ablation in patients with persistent atrial fibrillation and functional tricuspid regurgitation
Provisionally accepted- 1Shanghai General Hospital of Nanjing Medical University, Shanghai, China
- 2Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 3Shanghai General Hospital, Shanghai, China
- 4Suzhou Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Atrial fibrillation (AF) and tricuspid regurgitation (TR) frequently coexist and mutually worsen each other. However, the long-term effects of functional tricuspid regurgitation (FTR) on AF recurrence and the improvement of TR after radiofrequency catheter ablation (RFCA) remain unclear. Methods: This retrospective, single-center observational study involved 1690 patients with persistent atrial fibrillation (PsAF) who underwent AF ablation between January 2012 and June 2022. 153 paients with significant FTR were propensity matching 153 patients with no or mild FTR based on age, body mass index, and mitral regurgitation (MR) severity. Patients were followed up for at least 1 year. Procedural success was defined as freedom from any atrial tachyarrhythmia (>30 seconds) after the 3-month blanking period, off antiarrhythmic drugs. Significant FTR was defined as moderate to severe TR. Significant TR improvement was defined as a reduction in TR severity by ≥2 grades from pre- to post-ablation. Results: Among the observational cohort, 153 patients (9.1%) had significant FTR, the severity of which correlated with female sex, AF duration, atrial/ventricular remodeling, and NT-proBNP levels. During the 12-month follow-up, the procedural success rate was 67.6% (207/306). RFCA significantly reduced the proportion of RA and RV enlargement (P < 0.001), and improved the severity of FTR (P < 0.001). Logistic regression analyses showed that AF recurrence (odds ratio [OR] 18.244, 95% CI 7.500-52.427, P < 0.001)) was the strongest independent risk factor for non-significant TR improvement after ablation. After a mean follow-up of 5.3 ± 3.7 years, the overall procedural success rate was 47.4% (145/306). The overall success rate was significantly lower in patients with significant FTR compared to those with no or mild FTR (37.3% VS 57.5%, P < 0.001). A comparable difference was observed between ventricular FTR and no or atrial FTR (27.1% VS 53.4%, P < 0.001). Conclusions: Significant FTR was an independent predictor of AF recurrence in patients with PsAF undergoing RFCA. The long-term success was poor in the subgroups of significant FTR and those with ventricular FTR. Furthermore, successful RFCA was associated with significantly improved FTR in patients with PsAF.
Keywords: Atrial Fibrillation, Functional tricuspid regurgitation, Radiofrequency catheter ablation, Recurrence, persistent atrial fibllilation
Received: 26 Mar 2025; Accepted: 17 Oct 2025.
Copyright: © 2025 Liu, Wang, Li, Zhang, Chen, Wei, Lu, Wu, Dai, Liu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Genqinq Zhou, genqing.zhou@hotmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.